导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.93% | 2794/4773 |
| 近一周 | -2.19% | 1449/5462 |
| 近一月 | -4.15% | 2255/5421 |
| 近一季 | -7.42% | 2395/5209 |
| 近半年 | -2.81% | 2032/4920 |
| 近一年 | 0.56% | 2538/4366 |
| 近两年 | 44.97% | 1641/2954 |
| 近三年 | 27.19% | 1171/2253 |
| 成立以来 | 44.62% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.64% 3329/4961 |
12.10% 2227/5312 |
- - |
- - |
| 2025 | 19.36% 2224/4813 |
-1.07% 2566/3635 |
2.13% 1834/4076 |
17.87% 2414/4524 |
0.22% 2121/4813 |
| 2024 | 16.83% 755/3463 |
2.77% 705/2808 |
-1.19% 973/3014 |
16.71% 1373/3129 |
-1.42% 1697/3463 |
| 2023 | -9.00% 1086/2656 |
4.34% 976/2280 |
-3.92% 968/2385 |
-2.88% 778/2515 |
-6.53% 1812/2655 |
| 2022 | -19.13% 805/2207 |
-13.83% 851/1919 |
6.78% 606/2016 |
-13.56% 918/2113 |
1.67% 1180/2208 |
| 2021 | -3.11% 888/1822 |
-2.78% 703/1255 |
4.11% 922/1330 |
-5.57% 827/1466 |
1.36% 956/1822 |
| 2020 | 30.25% 524/1250 |
-9.47% 680/1028 |
13.23% 635/1067 |
12.45% 385/1164 |
13.01% 402/1184 |
| 2019 | 36.62% 353/1092 |
26.65% 389/739 |
-0.04% 202/788 |
1.26% 420/850 |
6.57% 592/918 |
| 2018 | - - |
- - |
- - |
-1.17% 235/660 |
-11.57% 318/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘沪深300ETF联接C VS. 长安沪深300非周期A(740101) |